MoonLake Immunotherapeutics MLTX Enterprise value

Enterprise value at other companies

Eli LillyLLY

$1.12T+51.8%

Oruka Therapeutics, Inc.ORKA

$2.38B+690%

Shattuck Labs, Inc.STTK

$372.63M+3,155%

Alumis Inc.ALMS

$2.77B+1,238%

Upstream Bio, Inc.UPB

$394.17M+52.4%

Kymera TherapeuticsKYMR

$9.39B+233%

FAQ

What is MoonLake Immunotherapeutics's enterprise value?

MoonLake Immunotherapeutics (MLTX) reported enterprise value of $1.14B in Q1 2026.

How has MoonLake Immunotherapeutics's enterprise value changed year-over-year?

MoonLake Immunotherapeutics's enterprise value decreased by 50.0% year-over-year, from $2.28B to $1.14B.

What is the long-term trend for MoonLake Immunotherapeutics's enterprise value?

Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's enterprise value has grown at a 16.0% compound annual growth rate (CAGR), from $372.59M to $674.96M.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.